PARIS (Reuters) - Activist shareholder Amber Capital, which is being sued by Lagardere (LAGA.PA), said on Monday the lawsuit was baseless and it would continue to seek strategy...
Keep Reading →
October 14 - Hedge Funds, Insider Trading - Comments
Crispin Odey, whose bearish bets led to his hedge fund suffering three successive years of losses, is firmly back on the rise. The Odey European Inc.
Keep Reading →
October 4 - Hedge Funds, Insider Trading - Comments
Please follow Baker Bros. Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about Baker Bros.
Keep Reading →
October 17 - Hedge Funds - Comments
You can access the original SEC filing by clicking here.
Keep Reading →
May 18 - Hedge Funds - Comments
Mott Capital Management is a long-only fund managed by Michael Kramer.
Keep Reading →
December 20 - Hedge Funds, News, Tech - Comments
March Altus Capital Management is a Connecticut-based long/short equity hedge fund that primarily invests in healthcare stocks.
Keep Reading →
November 15 - Hedge Funds, News - Comments
U.S. stock indexes are up substantially in Friday trading, with the S&P 500 hitting record highs, driven by a surprisingly strong jobs report out of the U.S.
Keep Reading →
August 5 - Earnings Report, Market Movers, News - Comments
While several hedge funds have suffered enormous losses this year due to their investments in biotech stocks, the performance of the leading biotech-focused hedge fund Baker Bros...
Keep Reading →
May 7 - Hedge Fund Analysis, Hedge Funds, News - Comments
U.S. equities inched up on Monday after fresh data displayed that consumer spending rose marginally in February.
Keep Reading →
March 28 - Market Movers, News - Comments
Baker Bros. Advisors is a New York City-based fund launched in 2000 by Julian and Felix Baker.
Keep Reading →
February 25 - Hedge Funds, News - Comments
Baker Bros. Advisors is one of the most famous healthcare-focused equity hedge funds in the world today.
Keep Reading →
December 9 - Hedge Fund Analysis, Hedge Funds, News - Comments
Shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Novavax, Inc.
Keep Reading →
November 2 - Market Movers, News - Comments
Hal Mintz's Sabby Capital has initiated a passive stake in Superconductor Technologies, Inc. (NASDAQ:SCON) according to a schedule 13G form filed with the SEC.
Keep Reading →
March 25 - Hedge Funds, News - Comments
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) spiked nearly 18% during Tuesday's intraday trading and hit a 52-week high of $46.48.
Keep Reading →
March 10 - Hedge Funds, News - Comments
Andreas Halvorsen's Viking Global is a fund with great returns over its 15-years old history. Since its foundation, Viking's flagship fund returned on average 19% per year.
Keep Reading →
December 10 - Hedge Funds, News - Comments
Small-cap picks from individual funds might provide investors with attractive investment options.
Keep Reading →
June 26 - Hedge Funds, News - Comments
In a new filing with the SEC, Julian Baker and Felix Baker’s Baker Bros. Advisors revealed new stake in Aquinox Pharmaceuticals Inc (NASDAQ:AQXP).
Keep Reading →
April 14 - Hedge Funds, News - Comments
Julian Baker and Felix Baker’s hedge fund, Baker Bros. Advisors, has recently tweaked its holdings in ACADIA Pharmaceuticals Inc.
Keep Reading →
March 10 - Hedge Funds, News - Comments
Legg Mason’s Bill Miller is struggling to find the ‘extraordinary’ value in the US he did last year, and said equity markets could rise even higher in 2014.
Keep Reading →
November 29 - Hedge Funds - Comments
At the moment, there are plenty of metrics investors can use to track their holdings. Two of the most under-the-radar are hedge fund and insider trading interest.
Keep Reading →
September 17 - News - Comments
With all of the heat generated by this biotech and its stock, it pays to pay attention to what Celgene Corporation (NASDAQ:CELG) says.
Keep Reading →
September 16 - News - Comments
In the financial world, there are a multitude of gauges shareholders can use to analyze Mr. Market. Two of the most innovative are hedge fund and insider trading interest.
Keep Reading →
September 6 - News - Comments
In the eyes of many of your fellow readers, hedge funds are viewed as overrated, outdated financial tools of a forgotten age.
Keep Reading →
September 5 - News - Comments
Now, according to many investors, hedge funds are seen as delayed, outdated financial tools of an era lost to time.
Keep Reading →
September 4 - News - Comments
At the moment, there are many methods investors can use to analyze Mr. Market. Some of the most innovative are hedge fund and insider trading sentiment.
Keep Reading →
August 30 - News - Comments
Healthcare is the most happening industry these days with new drugs on the line and investors injecting cash into companies with greater speculative growth.
Keep Reading →
August 3 - News - Comments
I began using Motley Fool’s CAPS as a way to disclose when I purchased and sold stocks, and my 97.2 rating showcases my last 10 months.
Keep Reading →
August 2 - News - Comments
Chances are that a few biotech companies will be scooped up by larger players over the coming months.
Keep Reading →
July 17 - News - Comments
According to IBISWorld, revenue of global biotechnology companies will surge to $262 billion this year, up by 12.7%, year-over-year.
Keep Reading →
July 16 - News - Comments
Only a handful of stocks have gained 200% in 2013, and five of those stocks are in the biotechnology industry.
Keep Reading →
July 12 - News - Comments
I began using Motley Fool’s “CAPS” late last year as a way for readers to track my new positions and to show the outcome of my investments that were chosen based on the ...
Keep Reading →
July 5 - News - Comments
ACADIA Pharmaceuticals Inc.
Keep Reading →
July 2 - News - Comments
The final catalyst is the one that I am reviewing today. I am looking at two companies that look to be attractive acquisition targets.
Keep Reading →
July 1 - News - Comments
According to most shareholders, hedge funds are seen as slow, old financial vehicles of the past.
Keep Reading →
June 24 - News - Comments
Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) was in 11 hedge funds' portfolio at the end of March. OPTR investors should be aware of a decrease in hedge fund interest lately.
Keep Reading →
June 12 - News - Comments
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’ 1,100% gain makes it one of the best performing stocks in the market.
Keep Reading →
June 12 - News - Comments
At the moment, there are tons of metrics shareholders can use to watch Mr. Market. A pair of the most underrated are hedge fund and insider trading movement.
Keep Reading →
June 10 - News - Comments
One of the best ways that retail investors can try to decide which stocks will make for a promising investment is to look at what the hedge funds are doing.
Keep Reading →
June 10 - Hedge Funds - Comments
Summer doesn't officially arrive for a few more weeks, but the first week of June packed some real heat.
Keep Reading →
June 10 - News - Comments
To most market participants, hedge funds are viewed as underperforming, outdated financial vehicles of the past.
Keep Reading →
June 7 - News - Comments
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) had a busy couple of months.
Keep Reading →
June 3 - News - Comments
If you'd owned these three biotech companies at the beginning of the year, you're sitting on around a triple compared to a relatively smaller-but-still-impressive 34% increase...
Keep Reading →
June 3 - News - Comments
Shaw is known as a math wizard, and a quantitative investing pioneer. His firm is reportedly extremely selective, hiring less than 1% of applicants -- and Amazon.com, Inc.
Keep Reading →
May 31 - Hedge Funds - Comments
Late last year I began using Motley Fool’s My CAPS as a way for readers to track my new investments and those that fit under the guidelines in my book Taking Charge With Value...
Keep Reading →
May 21 - News - Comments
Shares of Aegerion Pharmaceuticals, Inc.
Keep Reading →
May 20 - News - Comments
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has been on a solid run since early last year and it has continued to climb to new highs this year as well.
Keep Reading →
May 15 - News - Comments
To the average investor, there are a multitude of gauges investors can use to monitor their holdings.
Keep Reading →
April 15 - News - Comments
With the SPDR S&P Biotech Index up 35% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
April 14 - News - Comments
While the Dow Jones Industrial Average (INDEXDJX:.DJI) continues to climb to new heights on little more than a central bank-induced asset levitation scheme and closing the day...
Keep Reading →
April 12 - News - Comments
I had recommended staying away from the company for now because it looked too risky with a long wait before the company could complete its second phase 3 trial for pimavanserin...
Keep Reading →
April 11 - News - Comments
